ArticleEClinicalMedicine2025

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Junwen Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.